Hydroxychloroquine (HCQ) Prevention (TN22)

IRB
CHLA-18-00451
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-Risk for Type 1 Diabetes Mellitus

Hydroxychloroquine is given as an investigational drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes. See website for more details https://www.trialnet.org/our-research/prevention-studies/hydroxychloroquine-hcq

Study Details
Clinical Trials Government Identifier
NCT03428945
Keywords
hydroxychloroquine type 1 diabetes, t1d, glucose tolerance
Eligibility
1. Be identified as having 2 or more positive autoantibodies in the TrialNet Pathway to Prevention Study (TN01)
2. Be aged 3 or older and weigh more than 12 kg
3. Have normal glucose tolerance by oral glucose tolerance test within 7 weeks of the baseline study visit
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Debra Miller
Contact Email

dmiller@chla.usc.edu